Table IV.
ORs between ELAC2 haplotypes and the risk of prostate cancer
| Haplotype | Prevalence among controls, % (95% CI) | 0 copies | 1 copy | 2 copies | P-value* | |||
| Case/control | OR | Case/control | OR (95% CI) | Case/control | OR (95% CI) | |||
| All prostate cancer (global test P = 0.18) | ||||||||
| Hap1: TACGCAA | 26.2 (23.8–28.6) | 330/359 | 1.00 | 277/250 | 1.21 (0.96–1.53) | 52/47 | 1.20 (0.79–1.84) | 0.24 |
| Hap2: TGTACAA | 22.8 (20.5 –25.1) | 396/386 | 1.00 | 225/239 | 0.92 (0.73–1.16) | 38/31 | 1.21 (0.73–1.99) | 0.53 |
| Hap3: TGTGTGA | 12.2 (10.4–14.0) | 520/506 | 1.00 | 133/142 | 0.90 (0.69–1.18) | 6/8 | 0.73 (0.25–2.11) | 0.65 |
| Hap4: CGCGTAG | 8.9 (7.4–10.5) | 512/542 | 1.00 | 142/109 | 1.39 (1.05–1.85) | 5/5 | 0.96 (0.26–3.51) | 0.07 |
| Hap5: TGCGCAA | 8.4 (6.9–9.9) | 556/550 | 1.00 | 101/101 | 0.98 (0.72–1.35) | 2/5 | 0.43 (0.08–2.34) | 0.59 |
| Hap6: TGTGCAA | 5.0 (3.7–6.1) | 613/596 | 1.00 | 44/55 | 0.77 (0.50–1.18) | 2/5 | 0.39 (0.08–2.04) | 0.25 |
| Others | 16.5 | |||||||
| Sporadic prostate cancer (global test P = 0.03) | ||||||||
| Hap1: TACGCAA | 26.2 (23.8–28.6) | 321/354 | 1.00 | 271/245 | 1.25 (0.98–1.58) | 52/47 | 1.23 (0.80–1.89) | 0.16 |
| Hap2: TGTACAA | 22.9 (20.6–25.2) | 388/379 | 1.00 | 219/236 | 0.90 (0.71–1.14) | 37/31 | 1.18 (0.71–1.94) | 0.50 |
| Hap3: TGTGTGA | 11.9 (10.2–13.7) | 510/500 | 1.00 | 129/139 | 0.90 (0.68–1.19) | 5/7 | 0.71 (0.22–2.25) | 0.65 |
| Hap4: CGCGTAG | 9.0 (7.4–10.5) | 498/533 | 1.00 | 141/108 | 1.41 (1.06–1.87) | 5/5 | 0.97 (0.26–3.54) | 0.06 |
| Hap5: TGCGCAA | 8.5 (7.0–10.0) | 544/540 | 1.00 | 98/101 | 0.97 (0.71–1.33) | 2/5 | 0.42 (0.08–2.33) | 0.58 |
| Others | 21.5 | |||||||
*P-value was for testing the null hypothesis: OR1 copy = OR2 copies = 1.